Anavex Life Sciences Stock Crushed As European Alzheimer’s Drug Filing Pulled After EMA Pushback

All NewsMarch 25, 2026

Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer’s; EMA feedback prompts more data work.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Anavex Life Sciences Stock Crushed As European Alzheimer’s Drug Filing Pulled After EMA Pushback

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Walmart has a $160 pop-up canopy with sidewalls for $70

France pressures Germany over nuclear risks of long-range missiles

Ukraine’s freedom must be defended

Inside Ken Griffin’s $5bn Miami takeover

investingLive Asia-Pacific market news: KOSDAQ jumps nearly 5% as AI rebounds, oil firms